Clinical trial
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of…
NCT00083174 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00083174 |
|---|---|
| Title | Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| Official title | A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| Acronym | ExCel |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Grupo Espanol de Investigacion del Cancer de Mama UNICANCER |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | exemestane |
| Enrollment | 4,560 |
| Start date | Dec 3, 2004 |
| Primary completion | Mar 25, 2011 |
| Completion | Jan 22, 2018 |
| First posted | May 17, 2004 |
| Last update posted | Aug 25, 2023 |
| Countries | Canada, France, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: